Hyperbaric oxygen therapy alters bowel perfusion and improves outcomes in patients with treatment-refractory ulcerative colitis: a prospective pilot trial [0.03%]
高压氧治疗可改善难治性溃疡性结肠炎患者的肠道灌注及预后：一项前瞻性试点试验
Lieven Mulders,Maarten Pruijt,Joep Van Oostrom et al.
Lieven Mulders et al.
Background: Hyperbaric oxygen therapy (HBOT) delivers 100% oxygen in a pressurized chamber and enhances tissue oxygenation and neovascularization. While effective in radiation proctitis, acute severe ulcerative colitis, a...
Beyond the bowel: three rare complications of upadacitinib therapy in inflammatory bowel disease [0.03%]
乌帕替尼治疗炎症性肠病的三种罕见并发症
Sam Papasotiriou,Stephen B Hanauer
Sam Papasotiriou
Upadacitinib, a selective Janus kinase (JAK) 1 inhibitor, is approved for the treatment of moderate-to-severe inflammatory bowel disease (IBD). Although clinical trials and real-world studies support its efficacy and overall safety profile,...
Intestinal ultrasound reliably predicts fecal loading in patients with ulcerative colitis [0.03%]
结肠溃疡患者的肠道超声可靠地预测粪便负荷
Ryan Michael Mathias,Damjana Bogatic,Louisa Edwards et al.
Ryan Michael Mathias et al.
Background: Constipation commonly causes abdominal symptoms in ulcerative colitis (UC). Intestinal ultrasound (IUS) shows promise for assessing fecal loading, but parameters remain poorly defined. The primary aim of this ...
Comparative risk of serious infection in patients with ulcerative colitis treated with JAK inhibitors [0.03%]
乌来替尼与巴瑞克替尼治疗溃疡性结肠炎患者严重感染的比较风险研究
Antoine Meyer,Anaïs Bertrand,Antoine Martin et al.
Antoine Meyer et al.
Introduction: While Janus kinase inhibitors (JAKi) have been associated with an increased risk of serious infections compared with biologics in patients with ulcerative colitis (UC), data comparing the risk of infection a...
Comparative Study
Journal of Crohn's & colitis. 2026 May 8;20(5):jjag053. DOI:10.1093/ecco-jcc/jjag053 2026
Crohn's Disease Activity Index in the era of obesity: time to abandon it? [0.03%]
肥胖时代的克罗恩病活动指数：是时候放弃它了吗？
Xavier Treton,Carmen Stefanescu,Charlotte Mailhat et al.
Xavier Treton et al.
Obesity and metabolic syndrome are now common among patients with Crohn's disease, with prevalence rates approaching those of the general population. Yet the Crohn's Disease Activity Index (CDAI), which still underpins the design and interp...
Mirikizumab is associated with rapid and sustained improvements in novel measures of bowel urgency in moderately-to-severely active ulcerative colitis: 28-week results from the LUCENT-URGE trial [0.03%]
米里基朱单抗能快速且持续改善中至重度活动性溃疡性结肠炎患者的肠道紧急感：LUCENT-URGE试验的28周结果
Silvio Danese,Axel Dignass,David Laharie et al.
Silvio Danese et al.
Introduction: LUCENT-URGE (NCT05767021) was a Phase 3b, multicenter, open-label, single-arm study investigating bowel urgency (BU) in patients with moderately-to-severely active ulcerative colitis (UC) and BU at baseline,...
Bayesian prior elicitation on the efficacy of medical therapies in perianal fistulizing Crohn's disease [0.03%]
克罗恩病肛周瘘管形成症医疗疗法有效性的贝叶斯先验估计
Nurulamin M Noor,Haiyan Zheng,Zhi Cao et al.
Nurulamin M Noor et al.
Background & aims: Robust evidence for most licensed Crohn's disease therapies is lacking for perianal fistula outcomes due to a lack of dedicated clinical trials. This study aimed to use a Bayesian framework to determine...
Repeated opioid use during pregnancy in women with inflammatory bowel disease: prevalence and impact on birth outcomes in Denmark [0.03%]
丹麦孕期炎症性肠病女性重复使用阿片类药物及其对妊娠结局的影响
Sonia Friedman,Kevin Zeiss,Mette Wod et al.
Sonia Friedman et al.
Background and aims: In women with IBD, there are few options to treat pain during pregnancy and prescribers sometimes rely on opioids. We investigated the prevalence of repeated opioid use during the pregnancy period as ...
Safety of advanced therapies during pregnancy in women with immune-mediated inflammatory diseases: a systematic review and meta-analysis [0.03%]
关于自身免疫介导炎症性疾病孕妇使用先进疗法的安全性：系统回顾和.meta.分析
Ophelie Pingeon,Nathan Grellier,Bénédicte Coulm et al.
Ophelie Pingeon et al.
Background and aims: We aimed to assess the safety of advanced therapies, excluding tumor necrosis factor inhibitors (anti-TNFs), for the treatment of immune-mediated inflammatory diseases (IMIDs), on pregnancy and neonat...
What are the top 10 global research priorities for perianal Crohn's disease? The Global Perianal Crohn's Disease Priority Setting Partnership [0.03%]
国际骶骨克罗恩病研究优先事项伙伴关系(GPPjP)的前10项全球研究重点是什么？
Theo Pelly,Easan Anand,Jonathan Gower et al.
Theo Pelly et al.
Background and aims: Perianal Crohn's disease (pCD) is a debilitating condition with a prevalence of approximately 20% in patients within 10 years of diagnosis of CD. The condition significantly impacts patient quality of...